|Mr. Adam Sinding Steensberg M.D.||President & CEO||1.17M||N/A||1974|
|Ms. Henriette Wennicke||EVP & CFO||407.07k||N/A||1983|
|Mr. Ivan Mourits Moller||Executive VP & COO||N/A||N/A||1972|
|Mr. Mads Kronborg||Head of Investor Relations & Communication||N/A||N/A||N/A|
|Mr. Ravinder Chahil||Senior VP & General Counsel||N/A||N/A||1968|
|Ms. Christina Sonnenborg Bredal||Senior VP and Global Head of People & Organization||N/A||N/A||1985|
|Dr. Jens Damsgaard Mikkelsen M.D.||Head of Molecular Pharmacology||N/A||N/A||N/A|
|Dr. Danilo Verge||Head of Global Medical Affairs||N/A||N/A||N/A|
|Dr. David M. Kendall M.D.||Senior VP & Chief Medical Officer||N/A||N/A||1961|
|Lykke Romer||VP & Head of Finance and Accounting||N/A||N/A||N/A|
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Zealand Pharma A/S’s ISS governance QualityScore as of 1 December 2023 is 4. The pillar scores are Audit: 5; Board: 1; Shareholder rights: 1; Compensation: 9.